Evaluation of Aminohydantoins as a Novel Class of Antimalarial Agents
Lists
Only you see this
Abstract
Given the threat of drug resistance, there is an acute need for new classes of antimalarial agents that act via a unique mechanism of action relative to currently used drugs. We have identified a set of druglike compounds within the Tres Cantos Anti-Malarial Set (TCAMS) which likely act via inhibition of a Plasmodium aspartic protease. Structure-activity relationship analysis and optimization of these aminohydantoins demonstrate that these compounds are potent nanomolar inhibitors of the Plasmodium aspartic proteases PM-II and PM-IV and likely one or more other Plasmodium aspartic proteases. Incorporation of a bulky group, such as a cyclohexyl group, on the aminohydantion N-3 position gives enhanced antimalarial potency while reducing inhibition of human aspartic proteases such as BACE. We have identified compound 8p (CWHM-117) as a promising lead for optimization as an antimalarial drug with a low molecular weight, modest lipophilicity, oral bioavailability, and in vivo antimalarial activity in mice.
BibTeX
@inproceedings{meyers2013evaluation,
author = {Marvin J. Meyers and Micky D. Tortorella and Jing Xu and Limei Qin and Zhengxiang He and Xingfen Lang and Wentian Zeng and Wanwan Xu and Qin Li and Michael J. Prinsen and Francis M. Sverdrup and Christopher S. Eickhoff and David W. Griggs and Jonathan Oliva and Peter Ruminski and E. Jon Jacobsen and Mary Ann Campbell and David C. Wood and Daniel E. Goldberg and Xiaorong Liu and Yongzhi Lu and Xin Lü and Zhengchao Tu and Xiaoyun Lu and Ke Ding and Xiaoping Chen},
title = {{Evaluation of Aminohydantoins as a Novel Class of Antimalarial Agents}},
booktitle = {ACS},
year = {2013},
doi = {10.1021/ml400412x},
}Loading related content...